TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial – P&T Community

Posted: March 10, 2017 at 12:48 am

TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial
P&T Community
Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product candidate, AlloCSC-01, is currently in a Phase II clinical trial in Acute Myocardial Infarction (AMI). In addition, the second product candidate from the cardiac stem ...

and more »

Here is the original post:
TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial - P&T Community

Related Posts

Comments are closed.

Archives